Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Q1 2026 Earnings Presentation
24 slides from Expres2ion Biotech Holding Ab's earnings presentation, May 28, 2026
Slide 1: Innovative immunotherapies for a healthier world
Interim Report Q1 2026 Innovative immunotherapies for a healthier world Nasdaq First North: EXPRS2 ExpreS2ion Biotech Holding AB Company reg. no. 559033 - 3729
Slide 2: Forward-looking statements and disclaimer
Forward - looking statements and disclaimer Important information This report contains forward - looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar ex pressions identify forward - looking statements. All statements other than statements of historical fac
Slide 3: First quarter 2026 highlights
First quarter 2026 highlights Clinical progress, platform validation and disciplined execution across priority programmes ES2B - C001 VICI - Disease Cash and financing HER2 - targeted active immunotherapy Nipah programme advanced toward GMP readiness ExpreS2ion reported updated immunogenicity observ
Slide 4: A word from our CEO
A word from our CEO “The first quarter of 2026 demonstrated that our clinical strategy is working. Our data are getting stronger, our platform is advancing on multiple fronts, and we are taking the financial steps necessary to see Phase I clinical evaluation of ES2B - C001 through to completion. To
Slide 5: Pipeline Overview
Pipeline Overview A focused oncology lead asset, complemented by partnered infectious disease programmes and platform validation Target Pre - clinical Disease Project/Target ID Identification Pharmacology cGMP / Tox Phase I Phase II Phase III Collaboration Partner Platform 1 100% Breast Cancer ES2B
Slide 6: ES2B-C001 clinical update
ES2B - C001 clinical update Preliminary Phase I data support continued development of ES2B - C001 as a HER2 - targeted active immunotherapy Programme overview Early immunogenicity observations ES2B - C001 is ExpreS2ion’s lead oncology asset and a HER2 - targeted active immunotherapy being evaluated
Slide 7: ES2B-C001: current focus and next milestones
ES2B - C001: current focus and next milestones Strengthening the Phase I data package while preserving the planned end - 2026 readout What Q1 means The Q1 update strengthened the rationale for continued clinical development of ES2B - C001. The programme showed a more consistent and durable prelimina
Slide 8: Collaboration project updates
Collaboration project updates Partnered programmes continued to advance across manufacturing readiness, clinical validation and grant - funded platform development Nipah vaccine, VICI - Disease consortium Malaria vaccines, University of Oxford and Serum Institute of India During Q1 2026, ExpreS2ion
Slide 9: Malaria vaccine trial overview
Malaria vaccine trial overview ExpreS2 - enabled Oxford - led candidates continue across multiple clinical stages Vaccines in trial Trial Phase Sites Trial status Completion (est.) Q1 update VAC - 085 I Oxford, UK Concluded March 2025 ✓ Concluded 2025 Pfs48/45 in Matrix - M VAC - 099 Ib INSTech , BF
Slide 10: ExpreS2 platform and partnerships
ExpreS2 platform and partnerships Clinical, manufacturing and IP developments continued to validate the platform across proprietary and partnered programmes ExpreS2 is ExpreS2ion’s proprietary protein expression platform Clinical validation Manufacturing readiness Platform and IP strengthening based
Slide 11: Q1 2026 and post-period highlights
Q1 2026 and post - period highlights Selected significant corporate and operational events during the quarter and after period - end During Q1 2026 After period - end ES2B - C001 Phase I data updates Rights issue completed During Q1, ExpreS2ion reported updated immunogenicity observations from the o
Slide 12: Financial key figures
Financial key figures Group summary Q1 2026 Q1 2025 % Change Key income statement figures, SEK ‘000s Operating income 6,868 2,957 132% Cash and cash Operating Profit/loss after financial items -12,056 -12,968 -7% equivalents income Profit/loss -9,590 -11,440 -16% SEK 21.8m SEK 6.9m Key balance sheet
Slide 13: Financial overview
Financial overview Q1 2026 Highlights recognised during the period . Cash flow and liquidity Cash flow from operating activities amounted to Including the post - period rights issue proceeds, • Personnel costs remained broadly unchanged at SEK - 25.5 million in Q1 2026, compared with SEK - the Compa
Slide 14: Income statement - group
Income statement - group KSEK Q1 2026 Q1 2025 % change FY 2025 Operating income Net sales 1,038 1,332 -22% 3,657 Other operating income 5,830 1,625 259% 8,550 Total operating income 6,868 2,957 132% 12,207 Operating costs Raw materials & consumables -1,052 -565 86% -3,520 Research & development cost
Slide 15: Balance sheet - group
Balance sheet - group KSEK Q1 2026 YE 2025 % change Q1 2025 KSEK Q1 2026 YE 2025 % change Q1 2025 Assets Equity and liabilities Concessions, patents, licenses, trademarks and Share capital 15,690 15,690 0% 11,815 similar intellectual rights 1,407 1,503 -6% 1,848 Other capital contributions 172,715 2
Slide 16: Changes in equity - group
Changes in equity - group KSEK Q1 2026 Q1 2025 FY 2025 Opening balance 35,686 64,799 64,799 Issuance of new shares 0 0 12,096 Issuing expenses 0 0 -839 Vesting of share-based compensation 133 114 447 Exchange difference for the period 190 -2,308 -2,732 Profit-loss for the period -9,590 -11,440 -38,0
Slide 17: Cash flow statement - group
Cash flow statement - group KSEK Q1 2026 Q1 2025 % change FY 2025 Operating profit/loss -11,941 -12,663 -6% -44,270 Adjustments for items not included in the cash flow 435 512 -15% 1,917 Received interest 33 244 -86% 542 Interest paid -89 -10 790% -58 Income tax received 0 0 n/a 8,110 Cash flow from
Slide 18: Income statement - parent
Income statement - parent KSEK Q1 2026 Q1 2025 % change FY 2025 Operating income Net sales 0 0 n/a 558 Total operating income 0 0 n/a 558 Operating costs Other external costs -636 -485 31% -5,143 Personnel costs -193 -191 1% -752 Total operating costs -829 -676 23% -5,895 Operating profit/loss -829
Slide 19: Balance sheet - parent
Balance sheet - parent KSEK Q1 2026 YE 2025 % change Q1 2025 KSEK Q1 2026 YE 2025 % change Q1 2025 Assets Equity and liabilities Shares in group companies 24,724 56,128 -56% 55,734 Share capital 15,690 15,690 0% 11,815 Receivables from group companies 0 0 n/a 8,092 Restricted equity 15,690 15,690 0%
Slide 20: Changes in equity - parent
Changes in equity - parent KSEK Q1 2026 Q1 2025 FY 2025 Opening balance 55,932 77,504 77,504 Issuance of new shares 0 0 12,096 Issuing expenses 0 0 -839 Vesting of share-based compensation 133 114 447 Profit-loss for the period -32,340 -9,847 -33,276 Closing Balance 23,725 67,771 55,932 |20
Slide 21: Shareholder information
Shareholder information ExpreS2ion Biotech Holding AB’s share was List of largest shareholders listed on Nasdaq First North Growth Market on 29 July 2016. The trading name of the share is Name Number of shares held Share of votes and capital EXPRS2 and the ISIN code is SE0023261292. For Saxo Bank A/
Slide 22: Other matters
Other matters Company structure Operational risks and uncertainties Financial calendar ExpreS2ion Biotech Holding AB is the parent The risks and uncertainties to which ExpreS2ion’s company of the Group and has been listed on operations are exposed include pharmaceutical 4 June 2026 2025 Annual Repor
Slide 23: Declaration of The Board of Directors & CEO
Declaration of The Board of Directors & CEO Declaration The Board of Directors and CEO assure that the report presents a true and fair view of ExpreS2ion Biotech Holding AB’s business, operations, position and results. Hørsholm, Denmark 28 May 2026 ExpreS2ion Biotech Holding AB c/o Mindpark Rönnowsg
Slide 24: ExpreS2ion Biotech Holding AB
ExpreS2ion Biotech Holding AB Innovative immunotherapies for a healthier world c/o Mindpark Rönnowsgatan 8c www.expres2ionbio.com S - 252 25 Helsingborg www.expres2ionbio.com
ExpreS2ion Biotech Holding — Q1 2026 Earnings Presentation on 6ix